The name change and preferred conversion remove a critical overhang and allow the company to focus on advancing AT177. However, the massive S-3 resale registration (25M+ shares) and the unresolved Nasdaq listing status remain significant risks. Monitor for Nasdaq compliance updates and any progress on the potential $32M milestone payment tied to Phase 1 initiation.
Price Chart
Executive Summary
Adial Pharmaceuticals changed its name to Azora Therapeutics and will begin trading under ticker AZR on October 29, 2026, after stockholders approved the conversion of Series A preferred stock issued in the June 2026 acquisition of Azora Therapeutics. The company has a new executive leadership team and expects to initiate a Phase 1 trial of AT177, an oral AhR agonist for ulcerative colitis, in the first half of 2027, with cash funding operations into 2028.
Key Financial Metrics
Key Facts
- Stockholders approved conversion of Series A preferred stock into common stock, subject to beneficial ownership limitations.
- Company renamed to Azora Therapeutics, Inc.; common stock to trade under ticker AZR starting October 29, 2026.
- New executive leadership team appointed: Matt Davidson, Ph.D. as CEO; Julie Saiki, Ph.D. as CSO; Celia Economides as CFO; David Rubenstein, M.D., Ph.D. as Chief Scientist; Ajay Duggal, MBChB as Consulting CMO.
- Lead asset AT177, an oral colon-targeted AhR agonist for ulcerative colitis, is in IND-enabling studies with Phase 1 trial planned for first half of 2027.
- Private placement in June 2026 provided approximately $32 million in gross proceeds; potential additional $32 million upon Phase 1 initiation.
- Cash and cash equivalents expected to fund operations into 2028, including IND-enabling studies and Phase 1 start.
- Cross-filing context: S-3/A filed October 20, 2026 registers up to 25,148,970 shares for resale by selling stockholders, creating potential overhang of nearly 10x current shares outstanding; failure to obtain stockholder approval for preferred conversion by December 11, 2026 could trigger ~$51.9M cash settlement obligation.
Financial Impact
Private placement provided ~$32M gross proceeds; potential additional $32M upon Phase 1 initiation. Cash expected to fund operations into 2028. S-3/A registers ~25.1M shares for resale, creating potential dilution of nearly 10x current shares outstanding.
Risk Factors
- Massive potential dilution from the S-3 resale registration of ~25.1M shares (nearly 10x current shares outstanding).
- Nasdaq delisting risk remains unresolved; failure to maintain listing could impair liquidity.
- AT177 is still in IND-enabling studies with no clinical data; Phase 1 trial may fail or be delayed.
- Failure to obtain stockholder approval for preferred conversion by December 11, 2026 could trigger ~$51.9M cash settlement obligation that the company may not be able to cover.
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3390720 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | 8-K | $3.83 | awaiting T+60 | awaiting T+60 | $5.05 (+31.85%) |
Oct 28, 2026 1d ago | Press Release | $4.95 | awaiting T+60 | awaiting T+60 | $5.05 (+2.02%) |
Oct 27, 2026 2d ago | EFFECT | $3.71 | awaiting T+60 | awaiting T+60 | $5.05 (−36.12%) |
Oct 20, 2026 8d ago | 10-Q/A | $4.11 | awaiting T+60 | awaiting T+60 | $5.05 (−22.87%) |
Oct 20, 2026 8d ago | S-3/A | $4.11 | awaiting T+60 | awaiting T+60 | $5.05 (−22.87%) |
Oct 16, 2026 13d ago | DEFA14A | $3.62 | awaiting T+60 | awaiting T+60 | $5.05 (−39.50%) |
Oct 16, 2026 13d ago | 8-K | $3.62 | awaiting T+60 | awaiting T+60 | $5.05 (−39.50%) |
Sep 30, 2026 29d ago | Press Release | $4.13 | awaiting T+60 | awaiting T+60 | $5.05 (+22.28%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | awaiting T+60 | $5.05 (+14.77%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | awaiting T+60 | $5.05 (+14.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers